Tempest Therapeutics Q2 2024 GAAP EPS $(0.42) Misses $(0.40) Estimate
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics (NASDAQ:TPST) reported a Q2 2024 GAAP EPS of $(0.42), missing the analyst consensus estimate of $(0.40) by 5%.
August 08, 2024 | 9:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tempest Therapeutics reported a Q2 2024 GAAP EPS of $(0.42), missing the analyst consensus estimate of $(0.40) by 5%. This miss could lead to a negative short-term impact on the stock price.
The reported EPS miss indicates that the company's performance was below market expectations, which typically results in a negative reaction from investors. The 5% miss, while not massive, is significant enough to potentially cause a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100